CLDX News & Events

Reports Q4 revenue $121,000, consensus $1.46M. "The enthusiasm for barzolvolimab continues to build, driven by unparalleled efficacy data across multiple indications," said Anthony Marucci, co-founder, president and CEO of Celldex. "This is underscored by the completion of enrollment in our Phase 3 CSU studies six months ahead of guidance and strong interest from clinical trial sites in our recently initiated Phase 3 study in cold urticaria and symptomatic dermographism."

Celldex announced the completion of enrollment in the Company's global Phase 3 program of barzolvolimab in chronic spontaneous urticaria, which consists of two Phase 3 trials-EMBARQ-CSU1 and EMBARQ-CSU2. "Completing enrollment in these large Phase 3 CSU studies 6 months ahead of guidance highlights the significant unmet need in CSU and speaks to the excitement from patients and physicians about barzolvolimab and its potential as a best-in-disease treatment," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "We are extremely grateful to these patients, their families and their treating physicians for their enthusiasm and participation in the EMBARQ-CSU1 and EMBARQ-CSU2 studies. We look forward to reporting topline results later this year and remain focused on completing preparations to support bringing this much needed treatment to more than 1.8 million patients in the United States suffering from CSU."